175 related articles for article (PubMed ID: 11164108)
1. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K
Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
Asosingh K; Menu E; Van Valckenborgh E; Vande Broek I; Van Riet I; Van Camp B; Vanderkerken K
Clin Exp Metastasis; 2002; 19(7):583-91. PubMed ID: 12498387
[TBL] [Abstract][Full Text] [Related]
3. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
4. Selective in vivo growth of lymphocyte function- associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion.
Asosingh K; Vankerkhove V; Van Riet I; Van Camp B; Vanderkerken K
Exp Hematol; 2003 Jan; 31(1):48-55. PubMed ID: 12543106
[TBL] [Abstract][Full Text] [Related]
5. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
Asosingh K; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Blood; 2003 Apr; 101(8):3136-41. PubMed ID: 12480692
[TBL] [Abstract][Full Text] [Related]
7. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
Asosingh K; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2003 Jun; 63(12):3019-20. PubMed ID: 12810619
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.
Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Kawano MM
Leuk Lymphoma; 2003 Sep; 44(9):1477-81. PubMed ID: 14565647
[TBL] [Abstract][Full Text] [Related]
9. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6.
Mahmoud MS; Ishikawa H; Fujii R; Kawano MM
Blood; 1998 Nov; 92(10):3887-97. PubMed ID: 9808582
[TBL] [Abstract][Full Text] [Related]
10. The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells.
Descamps G; Pellat-Deceunynck C; Szpak Y; Bataille R; Robillard N; Amiot M
J Immunol; 2004 Oct; 173(8):4953-9. PubMed ID: 15470037
[TBL] [Abstract][Full Text] [Related]
11. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma.
Ishikawa H; Mahmoud MS; Fujii R; Abroun S; Kawano MM
Leuk Lymphoma; 2000 Sep; 39(1-2):51-5. PubMed ID: 10975383
[TBL] [Abstract][Full Text] [Related]
12. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma biology: lessons from the 5TMM models.
Vanderkerken K; Asosingh K; Croucher P; Van Camp B
Immunol Rev; 2003 Aug; 194():196-206. PubMed ID: 12846816
[TBL] [Abstract][Full Text] [Related]
14. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium.
Asosingh K; Günthert U; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2001 Apr; 61(7):2862-5. PubMed ID: 11306459
[TBL] [Abstract][Full Text] [Related]
15. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells (5TMM) and their interactions with the marrow microenvironment.
Menu E; Asosingh K; Van Riet I; Croucher P; Van Camp B; Vanderkerken K
Blood Cells Mol Dis; 2004; 33(2):111-9. PubMed ID: 15315788
[TBL] [Abstract][Full Text] [Related]
17. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
19. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.
Rawstron AC; Barrans SL; Blythe D; English A; Richards SJ; Fenton JA; Davies FE; Child JA; Jack AS; Morgan GJ
Br J Haematol; 2001 Jun; 113(3):794-802. PubMed ID: 11380472
[TBL] [Abstract][Full Text] [Related]
20. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
